Conatus Pharmaceuticals initiates phase 2b trial of emricasan Conatus Pharmaceuticals announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients with acute-on-chronic liver failure. The placebo-controlled, double-blind, multicenter clinical trial is designed to assess the pharmacokinetics and pharmacodynamics of emricasan in patients who have compensated or stable liver cirrhosis and who, at the time of study entry have been hospitalized for at least 24 hours due to acute deterioration of liver function. Conatus plans to use this trial to determine the dose of emricasan to be studied in the planned Phase 3 trial in ACLF. In addition to the Phase 2b trial in patients with ACLF, Conatus expects to initiate its planned Phase 2b/3 clinical trial of emricasan in patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection in 2H.
News For CNAT From The Last 14 Days
Check below for free stories on CNAT the last two weeks.
Conatus Pharmaceuticals gets orphan designation for liver transplant drug Conatus Pharmaceuticals announced that the U.S. FDA has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease.
Conatus Pharmaceuticals emricasan designated for orphan status Conatus Pharmaceuticals' emricasan received FDA orphan designation for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease. Reference Link